Where Will SpaceX Stock Be in 1 Year?

SpaceX stock has pulled back to around $161 after debuting at $150 and briefly topping $225.64, while fundamentals show revenue rising to $18.7B in 2025 (+34% YoY) and $4.7B in Q1 2026 (+16% YoY), with analysts forecasting 85% revenue growth in 2027 and a return to profitability. Despite the growth, the article flags extreme valuation risk with a trailing P/S of 106 versus Tesla (~15x) and Micron (~12x), suggesting the P/S multiple is more likely to fall than rise and price volatility could persist.

Analysis

This is less a SpaceX-specific call than a signal that the market is still willing to pay for scarcity, optionality, and Musk-adjacent narrative risk — until it isn’t. The immediate read-through for public equities is highest on the richest story stocks, especially PLTR, where any slight deceleration or guidance miss can force the multiple down faster than fundamentals move up. TSLA gets a weaker halo effect, but the business mix is too different for this to matter beyond sentiment.

The bigger second-order effect is private-market comp compression. If the upper end of late-stage software/space/AI marks soften, that slows mark-ups, makes follow-on rounds harder, and can keep the IPO window narrower for longer; that is a modest headwind for NDAQ’s listings pipeline and for any banker-dependent monetization of unicorns. Over 1-3 months, the risk is not earnings collapse but multiple contraction; over 6-18 months, the risk is that capital providers demand visible FCF earlier, which punishes names priced on TAM optionality.

The contrarian point is that the market may be overreacting to the headline multiple and underweighting the fact that high-growth businesses can grow into valuation very quickly if revenue inflection persists. What would falsify the de-rating thesis is a sustained re-acceleration in bookings/revenue plus a credible path to profitability that reduces the forward P/S denominator faster than expected. Absent that, the more likely outcome is sideways-to-down price action while the valuation normalizes through time rather than through earnings beats.

Key Decisions for Investors

• Short PLTR vs long NVDA for 1-3 months as a relative valuation hedge; target 5-10% relative underperformance in PLTR if rich-multiple names de-rate, and cover if PLTR re-accelerates bookings or NVDA guides down on AI demand.
• If you need convexity, buy PLTR 2-3 month put spreads on strength into any post-earnings rally; defined risk, best payoff if the market starts discounting slower growth and a lower terminal multiple.
• Do not add to TSLA on this print; treat it as a sentiment barometer rather than a fundamental beneficiary. Reassess only if Musk-linked optionality starts to show up in actual EPS/FCF revisions, not narrative.
• Set a watch item on NDAQ: if the next 1-2 months show a weaker IPO calendar or wider secondary discounts, that would confirm private-market de-rating and support a tactical short or underweight in exchange/listings exposure.
• No direct trade in SPCX from this note; wait for at least one cleaner secondary print or financing update before making it a position, since the current setup is still headline-driven rather than cash-flow driven.